Cited by 998Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record; 390 of the 393 references it cites were found in a registry or an index.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S, Duncan, G E, Marx, C E, Lieberman, J A·2005·Molecular Psychiatry

DOI 10.1038/sj.mp.4001556

Open this paper in CoChat — free account

Abstract

The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development. Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems. Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the pharmacological properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life. Moreover, the efficacy of antipsychotic drugs is limited prompting the clinical use of adjunctive pharmacy to augment the effects of treatment. In addition, the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiologic hypotheses. This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001556

Cites

390 of 390 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glutamate uptake
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D. A., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,416
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793

Show all 393 references

Research works printed but not linked: 15

Breier A, Wright P, Birkett M, Meehan K, David, Brook S . A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients, ACNP 39th Annual Meeting Abstract. American College of Neuropsychopharmacology: Puerto Rico, 2000.
Waddington J, Casey D . Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann: Woburn, MA, 2000, pp 3–13.
Carlsson A . Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr Opin CPNS Invest Drugs 2000; 2: 22–24.
Patel JK, Pinals DA, Breier A . Schizophrenia and other psychoses. In: Tasman A, Kay J, Lieberman JA (eds). PSYCHIATRY, 2nd edn. John Wiley & Sons, Ltd: Chichester, 2003, pp 1131–1206.
Ferris P . Ziprasidone. Curr Opin CPNS Invest Drugs 2000; 2: 58–70.
Nichols DE, Mailman RB . Substituted hexa-hydro[a]phenanthridines. US Patent 1995; 5: 134.
Nichols DE, Mailman RB . Fused isoquinolines as dopamine receptor ligands. US Patent 1999; 5: 110.
Danysz W . Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97–104.
Mansbach RS, Brooks EW, Sanner MA, Zorn SH . Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200. · DOI
Abi-Saab WM, D'Souza DC, Madonick SH, Krystal JH . Targeting the glutamate system. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 304–332.
Goff D, Berman I, Posever T, Leahy L, Lynch G . A preliminary dose-escalation trial of CX 516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 1999; 36: 280.
Bymaster FP . Possible role of muscarinic receptor agonists as therapeutic agents for psychosis. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 333–348.
Perry KW, Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Zhang W et al. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res 1999; 36: 117–118.
Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL . Application of pharmacogenetics to schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 85–110.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia trial design and protocol development. Schizophrenia Bull 2003; 29: 15–31. · DOI

Sorted by citations

Items 601–700 of 998

Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of AdjunctiveGarcinia mangostanaLinn. (Mangosteen) Pericarp for Schizophrenia
Turner, A., McGrath, J. J., Dean, O. M., Dodd, S., Baker, A., Cotton, S., Scott, J. G., Kavanagh, B. E., Ashton, M. M., Walker, A. J., et al. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.2.297 · Cited by 9
Higher levels of α7 nicotinic receptors, but not choline acetyltransferase, in the dorsolateral prefrontal cortex from a sub-group of patients with schizophrenia
Dean, B., Pavey, G., & Scarr, E. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.05.034 · Cited by 9
LY395756 promotes NR2B expression via activation of AKT/CREB signaling in the juvenile methylazoxymethanol mice model of schizophrenia
Li, M., Peng, Y., An, Y., Li, G., & Lan, Y. (2022) · Brain and Behavior · doi:10.1002/brb3.2466 · Cited by 8
Relationship of psychological symptoms, antipsychotics and social data with psychosocial function in schizophrenia patients in M alaysia
Norlelawati, A. T., Abdullah, K., Norsidah, K.-Z., Ramli, M., Azizi, W. S. W., & Tariq, A. R. (2013) · Asia-Pacific Psychiatry · doi:10.1111/appy.12089 · Cited by 9
Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility
Koranek, A., Smith, T. L., Mican, L. M., & Rascati, K. L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.01.043 · Cited by 9
Dose-related effects of clozapine and risperidone on the pattern of brain regional serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats
Batool, F., Hasnat, A., Haleem, M. A., & Haleem, D. J. (2010) · Acta Pharmaceutica · doi:10.2478/v1007-010-0014-y · Cited by 9
Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study
Innamorati, M., Baratta, S., Vittorio, C. D., Lester, D., Girardi, P., Pompili, M., & Amore, M. (2013) · Schizophrenia Research and Treatment · doi:10.1155/2013/423205 · Cited by 10
Molecular processes in an electrochemical clozapine sensor
Winkler, T. E., Lederer, S. L., Kim, E., Ben‐Yoav, H., Kelly, D. L., Payne, G. F., & Reza Ghodssi, A. (2017) · Biointerphases · doi:10.1116/1.4982709 · Cited by 9
Teaching Trainees to Negotiate Research Collaborations With Industry: A Mentorship Model
Merrill, D. B., Girgis, R. R., Bickford, L. C., Vorel, S. R., & Lieberman, J. A. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08121886 · Cited by 9
Self-citation
Arrestin Times for Developing Antipsychotics and β-Blockers
Houslay, M. D. (2009) · Science Signaling · doi:10.1126/scisignal.266pe22 · Cited by 9
Sensorimotor dysfunction of grasping in schizophrenia: a side effect of antipsychotic treatment?
Nowak, D. A. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.084749 · Cited by 9
Reversal of oxidative stress, cytokine toxicity and DNA fragmentation by quercetin in dizocilpine-induced animal model of Schizophrenia
Shahzad, S., Batool, Z., Afzal, A., & Haider, S. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01090-6 · Cited by 8
Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia
Kelebie, M. A., Kibralew, G., Tadesse, G., Rtbey, G., Aderaw, M., Endeshaw, W., Belachew, M., Muche, M., Getnet, D., & Fentahun, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-85832-3 · Cited by 8
Evidence of an interaction between FXR1 and GSK3β polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics
Rampino, A., Torretta, S., Gelao, B., Veneziani, F., Iacoviello, M., Marakhovskaia, A., Masellis, R., Andriola, I., Sportelli, L., Pergola, G., et al. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2021.26 · Cited by 7
Influence of the Co-Adsorbed Ions on the Surface-Enhanced Raman Scattering Spectra of Dopamine Adsorbed on Nanostructured Silver
Michałowska, A., Jędrzejewski, K., & Kudelski, A. (2022) · Materials · doi:10.3390/ma15175972 · Cited by 8
Neural changes induced by antipsychotic administration in adolescence: A review of studies in laboratory rodents
Moe, A. A. K., Scott, J. G., Burne, T. H. J., & Eyles, D. W. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116654776 · Cited by 8
Modeling schizophrenia with iPS cell technology and disease mouse models
Nakazawa, T. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.08.002 · Cited by 9
Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia
Phalguni, A., McCool, R., Wood, H., Sanderson, A., Rydevik, G., Franklin, B., & James, D. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000427 · Cited by 8
Sulpiride and refractory panic disorder
Nunes, E. A., Freire, R. C. R., dos Reis, M., Silva, A. C. D. O. E., Machado, S. E. D. C., Crippa, J. A. S., Dursun, S. M., Baker, G. B., Hallak, J. E. C., & Nardi, A. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2818-6 · Cited by 8
Involvement of Different Types of Dopamine Receptors in the Formation of Latent Inhibition of a Conditioned Passive Avoidance Reaction in Rats
Лоскутова, Л. В., Kostyunina, N. V., & Dubrovina, N. I. (2010) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-010-9285-5 · Cited by 9
Human Dopamine Receptors Interaction Network (DRIN): A systems biology perspective on topology, stability and functionality of the network
Podder, A., Jatana, N., & Latha, N. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.05.011 · Cited by 8
Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol
Malkoff, A., Weizman, A., Gozes, I., & Rehavi, M. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0122-8 · Cited by 7
Length of mechanical restraint following haloperidol injections versus oral atypical antipsychotics for the initial treatment of acute schizophrenia: A propensity-matched analysis from the Japanese diagnosis procedure combination database
Nakamura, M., Yasunaga, H., Haraguchi, T., Ando, S., Sugihara, T., Horiguchi, H., Ohe, K., Matsuda, S., & Fushimi, K. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.02.005 · Cited by 8
Chronic antipsychotic treatment: protracted decreases in phospho-TrkA levels in the rat hippocampus
Terry, A. V., Gearhart, D. A., Pillai, A., Zhang, G., & Bartlett, M. G. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709991040 · Cited by 8
The Prototypical Ranitidine Analog JWS-USC-75-IX Improves Information Processing and Cognitive Function in Animal Models
Terry, A. V., Buccafusco, J. J., Herman, E. J., Callahan, P. M., Beck, W. D., Warner, S., Vandenhuerk, L., Bouchard, K., Schwarz, G. M., Gao, J., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175422 · Cited by 8
Successful treatment of delusional disorder with low‐dose aripiprazole
Miyamoto, S., Miyake, N., Ogino, S., Endo, T., & Yamaguchi, N. (2008) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2008.01812.x · Cited by 8
Self-citation
A Novel Synthetic Interfering Peptide Tat-3L4F Attenuates Olanzapine-Induced Weight Gain Through Disrupting Crosstalk Between Serotonin Receptor 2C and Protein Phosphatase and Tensin Homolog in Rats
Wang, Y., Wang, D., Chen, Y., Fang, X., Yu, L., & Zhang, C. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa001 · Cited by 8
Sleep disturbance in schizophrenia
Godbout, R. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7440-3_8 · Cited by 8
Pharmacogenetic Studies Investigating the Adverse Effects of Antipsychotics
Lee, H. (2007) · Psychiatry Investigation · Cited by 8
Dietary Fructose and GLUT5 Transporter Activity Contribute to Antipsychotic-Induced Weight Gain
Palavicino‐Maggio, C. B., & Kuzhikandathil, E. V. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw037 · Cited by 8
The effect of rs1076560 (DRD2) and rs4680 (COMT) on tardive dyskinesia and cognition in schizophrenia subjects
Punchaichira, T. J., Kukshal, P., Triptish Bhatia, A., Deshpande, S. N., & Thelma, B. K. (2020) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000258 · Cited by 7
Photodegradation of typical psychotropic drugs in the aquatic environment: a critical review
Wang, C., Guo, R., Guo, C., Yin, H., & Xu, J. F. (2025) · Environmental Science Processes & Impacts · doi:10.1039/d4em00669k · Cited by 7
Clozapine versus olanzapine for people with schizophrenia
Lobos, C. A., Fonseca, C., Leucht, S., Marcelo Arancibia, M., & Cortés-Jofré, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013219 · Cited by 7
Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain
Schreyer, K. F., Leucht, S., Heres, S., & Steimer, W. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06331-9 · Cited by 7
Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review
Santarriaga, S., Gerlovin, K., Layadi, Y., & Karmacharya, R. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.02.029 · Cited by 7
Therapeutic Strategies in Schizophrenia
Conway, J. (2012) · InTech eBooks · doi:10.5772/30758 · Cited by 7
Neurobiology of nAChRs and cognition: A mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career
Terry, A. V., & Decker, M. W. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.010 · Cited by 7
Tardive Blepharospasm and Meige Syndrome during Treatment with Quetiapine and Olanzapine
Kılıç, A., Erten, E., & Özdemir, A. (2015) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2015.7411 · Cited by 7
Dopamine antagonist antipsychotics in diverted forensic populations
Cummings, M. A., Proctor, G. J., & Arias, A.-L. W. (2019) · CNS Spectrums · doi:10.1017/s1092852919000841 · Cited by 7
Association between DRD2 and ANKK1 polymorphisms with the deficit syndrome in schizophrenia
Michalczyk, A., Pełka-Wysiecka, J., Kucharska–Mazur, J., Wroński, M., Misiak, B., & Samochowiec, J. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00289-0 · Cited by 7
A novel and robust analytical method for the quantification of perospirone in human plasma using an LC–MS/MS system with self-internal standard calibration
Ding, J., Zhang, Y., Wan, S., Liu, Y., Cui, X., Zhao, C., Zhang, S., & Meng, Z. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.04.006 · Cited by 7
Cataleptogenic Effect of Haloperidol Formulated in Water-Soluble Calixarene-Based Nanoparticles
Kashapova, N. E., Kashapov, R. R., Ziganshinа, A. Y., Олегович, Н. Д., Ивановна, С. И., Salnikov, V. V., Khutoryanskiy, V. V., Moustafine, R. I., & Zakharova, L. Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030921 · Cited by 7
Design, synthesis, and preliminaryin vitroandin vivopharmacological evaluation of 2-{4-[4-(2,5-disubstituted thiazol-4-yl)phenylethyl]piperazin-1-yl}-1,8-naphthyridine-3-carbonitriles as atypical antipsychotic agents
Sekhar, K. V. G. C., Rao, V. S., Deuther‐Conrad, W., Reddy, A. S., Brust, P., & Kumar, M. M. K. (2010) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2010.537658 · Cited by 7
Olanzapine Causes a Leptin-Dependent Increase in Acetylcholine Release in Mouse Prefrontal Cortex
Wathen, A. B., West, E. S., Lydic, R., & Baghdoyan, H. A. (2012) · SLEEP · doi:10.5665/sleep.1686 · Cited by 7
Paliperidone Extended-Release Tablets (Invega)
Zacher, J. L., & Grady, S. E. (2007) · Psychopharm Review · doi:10.1097/01.idt.0000280816.38955.e1 · Cited by 7
Using a modified rabies immunoglobulin protocol in a crisis of unavailability: Ethical and practical challenges
Bharti, O. K. (2019) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2019.022 · Cited by 7
Antipsychotic Drug Treatment for Patients with Schizophrenia: Theoretical Background, Clinical Considerations and Patient Preferences
Nielsen, R. E., & Nielsen, J. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2175 · Cited by 7
Drug‐Induced and Iatrogenic Neurological Disorders
Kompoliti, K., & Horn, S. S. (2007) · Elsevier eBooks · doi:10.1016/b978-141603618-0.10055-4 · Cited by 7
Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting
Akkaya, C., Sarandöl, A., Cangür, Ş., & Kırlı, S. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.882 · Cited by 8
Do Research Procedures Pose Relatively Greater Risk for Healthy Persons Than for Persons With Schizophrenia?
Roberts, L. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi055 · Cited by 7
Disease relapse, all-cause mortality, and adverse events associated with long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia in Hong Kong: a population-based within-subject analysis
Wei, Y., Yan, V. K. C., Castle, D. J., Huang, C., Deng, E. K., Leung, S. K., Yiu, H. H. E., Lee, K. J., Lui, S. S. Y., Ng, V. W. S., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00268-8 · Cited by 7
Antipsychotic-induced hyperprolactinemia in Tourette syndrome
Rath, J. J. G., Deen, M. E. J., van Houten, H., de Bruijn, S. F. T. M., van Gerven, J., & Mul, D. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317705012 · Cited by 6
In vitro, ex vivo and in vivo evaluation of a novel metal-liganded nanocomposite for the controlled release and improved oral bioavailability of sulpiride
M’bitsi-Ibouily, G. C., Marimuthu, T., du Toit, L. C., Kumar, P., & Choonara, Y. E. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102909 · Cited by 6
Disrupted mossy fiber connections from defective embryonic neurogenesis contribute to SOX11-associated schizophrenia
Abulaiti, X., Wang, A., Zhang, H., Su, H., Gao, R., Chen, J., Gao, S., & Li, L. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04206-4 · Cited by 8
SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism
Erjavec, G. N., Grubor, M., Živković, M., Božina, N., Šagud, M., Perković, M. N., Mihaljević-Peleš, A., Pivac, N., & Štrac, D. Š. (2022) · Biomedicines · doi:10.3390/biomedicines10123237 · Cited by 8
Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment
Wang, Y., Liu, Z., Lu, J., Wang, W., Wang, L., Yang, Y., Wang, H., Ye, L., Zhang, J., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1161964 · Cited by 6
Adolescent neurostimulation of dopamine circuit reverses genetic deficits in frontal cortex function
Mastwal, S. S., Li, X., Stowell, R. D., Manion, M. T. C., Zhang, W., Kim, N., Yoon, K., Song, H., Ming, G., & Wang, K. H. (2023) · eLife · doi:10.7554/elife.87414 · Cited by 14
The role of paliperidone extended release for the treatment of bipolar disorder
Harrington, C., English, C., Marino, J., & Caballero, J. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s20675 · Cited by 6
Metabotropic Glutamate Receptor 2 Activators
Cid, J. M., Trabanco, A. A., & Lavreysen, H. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_48 · Cited by 6
Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers
Tcheremissine, O. V., Castro, M. A., & Gardner, D. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.634798 · Cited by 6
Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia
Essali, A., RIHAWI, A., Altujjar, M., Alhafez, B., Tarboush, A., & Hasan, N. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009546.pub2 · Cited by 7
Dopamine D2/D3 receptor binding of [123I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging
Huang, Y., Pai, C.-H., Cheng, K.-H., Kuo, W.-I., Chen, M. W., & Chang, K. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.04.133 · Cited by 6
Testosterone Depletion Induces Demethylation of Murine Reelin Promoter CpG Dinucleotides: A Preliminary Study
da Silva, V. A. M., Dantas, M. D. S., Silva, L. A. D. C., Carneiro, J. G., & Schamber‐Reis, B. L. F. (2015) · BioMed Research International · doi:10.1155/2015/286369 · Cited by 6
Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents
Etiévant, A., Betry, C., & Haddjeri, N. (2010) · The Open Neuropsychopharmacology Journal · Cited by 6
Effects of repeated quetiapine treatment on conditioned avoidance responding in rats
Gao, J., Feng, M., Swalve, N. L., Davis, C., Sui, N., & Li, M. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.011 · Cited by 6
Pharmacogenomics of Antipsychotic Drugs
Zhang, J., & Malhotra, A. K. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0113-1 · Cited by 6
The Benefits of Antipsychotic Drugs
Zhang, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803376-0.00014-9 · Cited by 6
Electron Transfer-Mediated Photodegradation of Phototoxic Antipsychotic Drug Quetiapine
Gupta, A., Kumar, Y., Zaheer, M. R., Roohi, R., Iqbal, S., & Iqbal, J. (2021) · ACS Omega · doi:10.1021/acsomega.1c05302 · Cited by 6
Glutamate transport inhibitors as targets for treating psychosis
Dunlop, J., & Marquis, K. L. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.10.005 · Cited by 6
Human aldrin poisoning.
Carvalho, W. A., Matos, G. B., Cruz, S. L., & Rodrigues, D. S. (1991) · PubMed · Cited by 6
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms
Bugarski‐Kirola, D., Liu, I.-Y., Arango, C., & Marder, S. R. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf034 · Cited by 5
Inhibitory effects of the atypical antipsychotic, clozapine, on voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells
Kang, M., Heo, R., Park, S., Mun, S., Park, M., Han, E., Han, J., Chun, W., Ha, K., Park, H., et al. (2022) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2022.26.4.277 · Cited by 5
Activity system, schizotypal personality, and mentalization: A study between halted activity and COVID-19 conducted in Henan, China
Maouch, M. E., Wang, Y., Jin, Z., Tamutana, T. T., Zhao, K., & Liu, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.930842 · Cited by 6
Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol
Jieu, B., Sykorova, E. B., Rohleder, C., Marcolini, E., Hoffmann, A., Koethe, D., Leweke, F. M., & Couttas, T. A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116005 · Cited by 6
Differential responses to JNJ‐37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague–Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics
Waal, E. J. D., Desmidt, M., Korte, S., Niehoff, M. O., Chase, K., Arrowsmith, W., & Lampo, A. (2013) · Journal of Applied Toxicology · doi:10.1002/jat.2916 · Cited by 5
Synthesis and preliminary screening of novel N-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}acetamides as potential atypical antipsychotic agents
Sekhar, K. V. G. C., Rao, V. S., & Krishna, M. M. (2008) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360802447750 · Cited by 5
Pharmacogenetic Testing in Schizophrenia and Posttraumatic Stress Disorder
Ramey-Hartung, B., El-Mallakh, R. S., & Reynolds, K. K. (2008) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2008.08.004 · Cited by 5
Early prediction of blonanserin response in Japanese patients with schizophrenia
Kishi, T., Matsuda, Y., Fujita, K., & Iwata, N. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s70227 · Cited by 5
Quels critères pour un traitement antipsychotique idéal ?
Bordet, R. (2015) · L Encéphale · doi:10.1016/j.encep.2014.12.001 · Cited by 5
Utilization Pattern of Antipsychotics at a Tertiary Care Hospital in Oman
Za’abi, M. A. (2014) · African Journal of Psychiatry · doi:10.4172/psychiatry.1000171 · Cited by 5
Risperidone induces long-lasting changes in the conditioned avoidance response and accumbal gene expression selectively in animals treated as adolescents
Moe, A. A. K., Kurniawan, N. D., Alexander, S., Cui, X., Burne, T. H. J., & Eyles, D. W. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.035 · Cited by 5
Uso de asenapina en la práctica clínica: recomendaciones de un panel de expertos
Vieta, E., Montes, J. M. G., Iborra, P., Mozos, A., Sáez, C., & Benabarre, A. (2018) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2018.03.007 · Cited by 5
The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study
van der Lee, A. P. M., Önsesveren, I., Wierdsma, A. I., van Westrhenen, R., Beekman, A. T. F., de Haan, L., & Mulder, N. C. L. (2021) · CNS Drugs · doi:10.1007/s40263-021-00802-3 · Cited by 5
Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
Sakai, S., Morimoto, Y., Matsuzaka, Y., Nakano, T., Kanegae, S., Imamura, A., & Ozawa, H. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12200 · Cited by 5
An Unusual Cause of Persistent Tachycardia: Atypical Neuroleptic Malignant Syndrome
Duhan, S., Keisham, B., & Jain, A. (2023) · Cureus · doi:10.7759/cureus.36428 · Cited by 5
Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
Zhao, M., Qin, B., Mao, Y., Zhang, Y., Zhao, R., Wang, A., Wang, H., Zhao, J., & Wang, C. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s407259 · Cited by 6
Role of Serotonin in Schizophrenia
Yavaşçi, E. Ö., & Akkaya, C. (2012) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.5455/cap.20120415 · Cited by 5
Comparative molecular field analysis and hologram quantitative structure activity relationship studies of pyrimidine series as potent phosphodiesterase 10A inhibitors
Rostami, E. G., & Fatemi, M. H. (2018) · Journal of the Chinese Chemical Society · doi:10.1002/jccs.201700435 · Cited by 5
Valproate and high dosage of zotepine induced acute delirium: a case report
Hsu, W., Kuo, S., Huang, S., Chang, T., & Chiu, N. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04119.x · Cited by 5
The Correlation between Osteoporosis Occurrences in Both Schizophrenia and Parkinson’s Disease
Radaei, F., Darvishi, A., & Gharibzadeh, S. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00083 · Cited by 5
The quest for developing new treatments from imaging techniques: promises, problems and future potential
Minzenberg, M., & Carter, C. S. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.8.1029 · Cited by 5
Antipsychotic Medication Use in the Elderly Patient
Malone, M., Carnahan, R. M., & Kutscher, E. C. (2007) · Journal of Pharmacy Practice · doi:10.1177/0897190007304982 · Cited by 6
Genetics and diagnostic refinement
van den Oord, E. J. C. G., McClay, J. L., York, T. P., Murrelle, L., & Robles, J. R. (2006) · Behavior Genetics · doi:10.1007/s10519-006-9135-y · Cited by 5
Eccentric indices based QSPR evaluation of drugs for schizophrenia treatment
Mansha, M., Ahmad, S., & Raza, Z. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42222 · Cited by 4
Development, validation, and application of a simple UPLC–MS/MS method for simultaneous quantification of five traditional antipsychotics in human plasma
Fan, L., An, J., Cui, Y., & Dong, Z. (2021) · Biomedical Chromatography · doi:10.1002/bmc.5143 · Cited by 4
Antipsychotic- and Anxiolytic-like Properties of a Multimodal Compound JJGW08 in Rodents
Żmudzka, E., Lustyk, K., Głuch‐Lutwin, M., Mordyl, B., Zakrzewska-Sito, A., Mierzejewski, P., Jaśkowska, J., Kołaczkowski, M., Sapa, J., & Pytka, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415929 · Cited by 4
Zebrafish as a Promising Model in Translational Neurobiology and Biomedicine
Kolesnikova, T. O., Ilyin, N. P., Kotova, M. M., & Калуев, А. В. (2023) · Успехи физиологических наук · doi:10.31857/s0301179823030037 · Cited by 4
Modular Synthesis of Heterobenzylic Amines via Carbonyl Azinylative Amination
Rafaniello, A. A., Kumar, R., Phillips, R. C., & Gaunt, M. J. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202408287 · Cited by 4
Effects of positive mGlu5 modulation on D 2 signaling and nicotine-conditioned place preference: Mechanisms of epigenetic inheritance in a transgenerational model of drug abuse vulnerability in psychosis
Peeters, L. D., Wills, L. J., Cuozzo, A. M., Ahmed, C. D., Massey, S. R., Chen, W., Chen, Z., Wang, C., Gass, J. T., & Brown, R. W. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241292902 · Cited by 4
Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
Woo, Y. S., Park, J. E., Kim, D., Sohn, I., Hwang, T.-Y., Park, Y. M., Jon, D., Jeong, J., & Bahk, W. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.4.458 · Cited by 4

Authors: Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A.
Affiliations: St. Marianna University School of Medicine (JP)
University of North Carolina at Chapel Hill (US)
Duke Medical Center (US)
Corresponding author: Lieberman, J A
Venue: Molecular Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2004-08-03
Volume: 10
Issue: 1
Pages: 79-104
ISSN: 1359-4184 (ISSN-L)
1476-5578
DOI: 10.1038/sj.mp.4001556
OpenAlex: W2132980997
Cited by: 988
References: 393
Citations by year: 2026: 23 · 2025: 25 · 2024: 32 · 2023: 40 · 2022: 37 · 2021: 40 · 2020: 45 · 2019: 42 · 2018: 40 · 2017: 41 · 2016: 54 · 2015: 52 · 2014: 46 · 2013: 72 · 2012: 66
FWCI: 4.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Molecular Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (MH064065, P50MH064065)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, dopamine D2 receptor, atypical antipsychotics, partial dopamine agonist, typical antipsychotics, mechanism of action, antipsychotic adverse effects, adjunctive pharmacotherapy, antipsychotic drug development, schizophrenia pathophysiology
MeSH terms: Behavioral Symptoms, Humans, Schizophrenia, Antipsychotic Agents, Drug Design, Dopamine Agents, Receptors, Dopamine D2, Receptors, Glutamate, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks